Clinical Takeaway
In this randomized, double-blind, placebo-controlled trial, CBD did not demonstrate superiority over placebo in reducing pain among patients with fibromyalgia. The findings do not support the use of CBD as an effective treatment for fibromyalgia pain based on current evidence. Patients and clinicians should weigh these results carefully when considering CBD for fibromyalgia management.
#7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Citation: Rasmussen Marianne Uggen et al.. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.. Annals of the rheumatic diseases. 2026. PMID: 40846590.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This randomised controlled trial provides the first rigorous evidence evaluating CBD efficacy in fibromyalgia, a condition affecting millions of patients who currently lack FDA-approved pharmacological options and often experience poor tolerance to conventional analgesics. The findings directly inform clinical decision-making regarding whether CBD represents a viable therapeutic alternative or adjunct for fibromyalgia pain management, with implications for reducing polypharmacy and opioid exposure in this patient population. Given the widespread off-label use of CBD in fibromyalgia despite limited evidence, this study addresses a critical gap between current clinical practice and the evidence base supporting treatment recommendations.
Quality Gate Alerts:
- Preclinical only
Abstract: OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.
💊 This Danish randomised controlled trial addresses a significant evidence gap regarding cannabidiol’s role in fibromyalgia management, a condition where patients often seek cannabis-based therapies despite limited rigorous data. While the double-blind, placebo-controlled design strengthens internal validity, the single-centre recruitment from a specialised outpatient clinic may limit generalisability to diverse fibromyalgia populations, and the abstract does not clarify dosing regimens, treatment duration, or whether concomitant analgesics were controlled. Important confounders such as baseline pain severity distribution, comorbid psychiatric conditions (common in fibromyalgia), and individual variation in CBD metabolism warrant careful review of the full dataset. If CBD demonstrated superiority over placebo, this would provide valuable evidence to guide patient counselling; conversely, a null finding would help redirect patients toward interventions with stronger evidence and reduce potentially costly out-of-pocket spending on unproven remedies. Clinicians should await the full publication to assess whether CBD